31,562 Shares in Dyne Therapeutics, Inc. $DYN Bought by State of New Jersey Common Pension Fund D

Posted by Brian Himes on May 12th, 2026

State of New Jersey Common Pension Fund D purchased a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 31,562 shares of the company’s stock, valued at approximately $617,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Dyne Therapeutics during the 1st quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Dyne Therapeutics by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its position in Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after purchasing an additional 366,183 shares in the last quarter. Caxton Associates LLP bought a new position in Dyne Therapeutics during the first quarter worth about $157,000. Finally, Creative Planning lifted its stake in Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after purchasing an additional 2,797 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Activity

In related news, Director Jason P. Rhodes sold 287,956 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the transaction, the director owned 11,663 shares in the company, valued at $229,527.84. This represents a 96.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,552,911 shares of company stock valued at $29,694,469 over the last three months. Insiders own 20.77% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright lowered their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. JPMorgan Chase & Co. dropped their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Finally, Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.14.

View Our Latest Analysis on Dyne Therapeutics

Dyne Therapeutics Stock Up 4.8%

NASDAQ DYN opened at $18.46 on Tuesday. The stock’s 50 day simple moving average is $18.12 and its 200 day simple moving average is $18.60. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The firm has a market cap of $3.05 billion, a PE ratio of -5.21 and a beta of 1.08. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) earnings per share. As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

(Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).

Institutional Ownership by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.